Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 5/20 | 0.57 |
| ▸ | CTSL | P07711 | 3/20 | 0.57 |
| ▸ | CTSS | P25774 | 3/20 | 0.57 |
| ▸ | CTSB | P07858 | 2/20 | 0.57 |
| ▸ | ATM | Q13315 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.54 |
| ▸ | ELANE | P08246 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2949041 | 1.00 | CTSK (0.57) | CTSKCTSLCTSSCTSBATM | |
| SCHEMBL6897142 | 0.94 | CTSK (0.54) | CTSKCTSLCTSSCTSBATM | |
| SCHEMBL15080869 | 0.92 | CTSK (0.61) | CTSKCTSLCTSSCTSBATM | |
| SCHEMBL30946598 | 0.92 | CTSK (0.61) | CTSKCTSLCTSSCTSBATM | |
| SCHEMBL11004145 | 0.89 | CTSK (0.53) | CTSKCTSLCTSSCTSBATM | |
| SCHEMBL11004153 | 0.89 | CTSK (0.53) | CTSKCTSLCTSSCTSBATM | |
| SCHEMBL6320137 | 0.89 | METAP2 (0.48) | CTSKCTSLCTSSCTSBATM | |
| SCHEMBL5412160 | 0.88 | MAPT (0.61) | CTSKCTSLCTSSCTSBATM | |
| SCHEMBL5075275 | 0.88 | CTSK (0.60) | CTSKCTSLCTSSCTSBATM | |
| SCHEMBL939737 | 0.88 | MAPT (0.61) | CTSKCTSLCTSSCTSBATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112516388-B | Domain-controllable osteochondral repair composite scaffold and preparation method thereof | 四川大学 | 2021-11-02 | — | — | CN | disclosed |
| CN-112516388-A | Domain-controllable osteochondral repair composite scaffold and preparation method thereof | 四川大学 | 2021-03-19 | — | — | CN | disclosed |
| US-8871785-B2 | Antiviral phosphonate analogs | GILEAD SCIENCES, INC. (US) | 2014-10-28 | — | — | US | disclosed |
| US-8329926-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2012-12-11 | — | — | US | disclosed |
| US-8324179-B2 | Nucleoside analogs for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-8318701-B2 | Phosphonate analogs of HIV inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2012-11-27 | — | — | US | disclosed |
| US-20110288053-A1 | ANTIVIRAL PHOSPHONATE ANALOGS | GILEAD SCIENCES, INC. (US) | 2011-11-24 | — | — | US | disclosed |
| US-8022083-B2 | Antiviral phosphonate analogs | GILEAD SCIENCES, INC. (US) | 2011-09-20 | — | — | US | disclosed |
| EP-2070914-B1 | New antagonist derivatives of the vitronectin receptor, method for their preparation, their application as medicine and pharmaceutical compositions containing them | GALAPAGOS SAS (FR) | 2011-08-03 | — | — | EP | disclosed |
| US-7763621-B2 | Vitronectin receptor antagonist derivatives, method for preparing same, use thereof as medicines and pharmaceutical compositions containing same | GALAPAGOS SAS (FR) | 2010-07-27 | — | — | US | disclosed |
| US-20090202470-A1 | Phosphonate Analogs of Hiv Inhibitor Compounds | GILEAD SCIENCES, INC. (US) | 2009-08-13 | — | — | US | disclosed |
| US-20090149476-A1 | Novel vitronectin receptor antagonist derivatives, method for preparing same, use thereof as medicines and pharmaceutical compositions containing same | GALAPAGOS SAS | 2009-06-11 | — | — | US | disclosed |
| US-20090029939-A1 | Pre-organized tricyclic integrase inhibitor compounds | GILEAD SCIENCES, INC. | 2009-01-29 | — | — | US | disclosed |
| US-20090012037-A1 | Antiviral Compounds | GILEAD SCIENCE, INC. (US) | 2009-01-08 | — | — | US | disclosed |
| US-7407965-B2 | Phosphonate analogs for treating metabolic diseases | GILEAD SCIENCES, INC. (US) | 2008-08-05 | — | — | US | disclosed |
| US-20080171724-A1 | Phosphonate Derivatives of Mycophenolic Acid | GILEAD SCIENCES, INC. (US) | 2008-07-17 | — | — | US | disclosed |
| US-20080167270-A1 | ANTI-INFECTIVE PHOSPHONATE ANALOGS | BOOJAMRA CONSTANTINE G | 2008-07-10 | — | — | US | disclosed |
| US-20070281907-A1 | Kinase Inhibitor Phosphonate Conjugates | GILEAD SCIENCES, INC. | 2007-12-06 | — | — | US | disclosed |
| US-7253180-B2 | Pre-organized tricyclic integrase inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2007-08-07 | — | — | US | disclosed |
| US-20060052398-A1 | Novel vitronectin receptor antagonist derivatives, method for preparing same, use thereof as medicines and pharmaceutical compositions containing same | GALAPAGOS NV (BE) | 2006-03-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060052398-A1 | Novel vitronectin receptor antagonist derivatives, method for preparing same, use thereof as medicines and pharmaceutical compositions containing same | ADGRF1, C5AR2, ADGRE5 | CTSK 1391/4885CTSL 447/4885CTSS 1246/4885 |
| US-20090202470-A1 | Phosphonate Analogs of Hiv Inhibitor Compounds | PIK3CA, TYMP, ITPA | CTSK 1880/4885CTSL 1332/4885CTSS 1647/4885 |
| US-20080167270-A1 | ANTI-INFECTIVE PHOSPHONATE ANALOGS | PHOSPHO1, PGLS, PSPH | CTSK 1131/4885CTSL 273/4885CTSS 857/4885 |
| US-20110288053-A1 | ANTIVIRAL PHOSPHONATE ANALOGS | TYMP, ITPA, PNP | CTSK 2359/4885CTSL 1567/4885CTSS 2339/4885 |
| US-20090029939-A1 | Pre-organized tricyclic integrase inhibitor compounds | MUS81, CDKL4, INTS6 | CTSK 2845/4885CTSL 475/4885CTSS 736/4885 |
| US-20090149476-A1 | Novel vitronectin receptor antagonist derivatives, method for preparing same, use thereof as medicines and pharmaceutical compositions containing same | ADGRF1, C5AR2, ADGRE5 | CTSK 1391/4885CTSL 447/4885CTSS 1246/4885 |
| US-20090012037-A1 | Antiviral Compounds | EIF2AK2, MAVS, ITPA | CTSK 1726/4885CTSL 1165/4885CTSS 1463/4885 |
| US-20080171724-A1 | Phosphonate Derivatives of Mycophenolic Acid | PPP5C, DUSP15, DUSP4 | CTSK 4249/4885CTSL 4359/4885CTSS 4508/4885 |
| US-20070281907-A1 | Kinase Inhibitor Phosphonate Conjugates | PIK3CA, PNKP, PLK1 | CTSK 836/4885CTSL 3081/4885CTSS 3275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.